Avadel Pharmaceuticals plc - Laporan Laba Rugi (TTM)

Avadel Pharmaceuticals plc
DE ˙ DB ˙ US05337M1045
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Avadel Pharmaceuticals plc menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 33 22 10 0 0 1 9 28 55 95 138 169 194 221
Change (%) -32.99 -54.82 -100.00 NaN 468.85 228.59 97.19 72.56 45.20 22.41 14.98 13.69
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 8 6 3 0 0 0 0 1 2 5 11 15 19 23
Change (%) -29.60 -42.79 -100.00 NaN 325.00 452.94 179.91 116.22 117.93 36.92 26.54 18.51
% of Revenue 24.47 25.71 32.55 2.41 1.80 3.03 4.29 5.38 8.08 9.03 9.94 10.36
Gross Operating Profit 25 17 7 0 0 1 8 27 53 90 127 154 175 198
Change (%) -34.09 -58.98 -100.00 NaN 472.40 224.48 94.61 70.60 41.07 21.13 13.83 13.16
% of Revenue 75.53 74.29 67.45 97.59 98.20 96.97 95.71 94.62 91.92 90.97 90.06 89.64
SG&A 31 32 36 44 56 102 127 152 176 171 178 181 178 185
Change (%) 4.22 9.56 22.76 29.51 81.29 24.49 19.09 15.92 -2.77 3.94 1.87 -1.68 3.77
% of Revenue 93.29 145.09 351.84 6,839.77 1,496.89 542.52 318.93 179.71 128.64 107.05 91.54 83.55
R&D 23 20 19 21 20 17 17 13 12 12 13 15 16 17
Change (%) -10.78 -8.21 14.42 -5.54 -15.08 -0.49 -22.62 -5.75 -1.38 7.74 14.42 8.46 1.24
% of Revenue 68.75 91.53 185.95 1,151.14 201.37 47.42 22.67 12.96 9.61 8.99 8.48 7.55
OpEx 63 59 58 65 77 120 145 166 191 188 202 212 214 224
Change (%) -6.02 -2.10 12.63 17.94 55.86 20.99 14.61 15.03 -1.20 7.28 4.63 1.09 4.91
% of Revenue 188.35 264.15 572.35 7,993.32 1,700.06 592.97 345.89 198.04 146.32 125.07 109.96 101.47
Operating Income -29 -37 -48 -65 -77 -118 -136 -138 -136 -93 -64 -42 -19 -3
Change (%) 24.50 30.02 36.48 17.94 53.91 15.31 1.24 -1.64 -31.20 -31.39 -33.75 -54.33 -83.27
% of Revenue -88.35 -164.15 -472.35 -7,893.32 -1,600.06 -492.97 -245.89 -98.04 -46.32 -25.07 -9.96 -1.47
Interest Expense -13 -13 -12 -10 -9 -12 -11 -10 -9 -10 -10 -11 -10 -10
Change (%) 0.92 -9.70 -11.14 -12.76 36.03 -12.82 -8.35 -6.75 4.57 8.73 3.32 -3.27 -3.45
% of Revenue -38.63 -58.18 -116.27 -827.07 -126.76 -35.35 -16.72 -10.13 -7.59 -6.40 -5.39 -4.58
Net Income 16 7 -6 -56 -66 -143 -159 -160 -157 -106 -73 -49 -26 -3
Change (%) -54.85 -179.00 908.77 18.39 115.38 11.29 0.84 -2.15 -32.27 -31.68 -32.72 -45.92 -88.93
% of Revenue 46.71 31.47 -55.02 -9,546.26 -1,867.69 -573.17 -284.42 -111.64 -52.53 -28.87 -13.58 -1.32

Source: Capital IQ

Other Listings
US:AVDL US$ 15.76
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista